By Sandra Fish Dinakar Singh, chief executive officer of TPG-Axon Capital Management, discusses his daughter Arya's genetic disease and how it led him to establish and fund the Spinal Muscular Atrophy Foundation. You've probably never heard of Spinal
(NASDAQ:RGEN) said Wednesday that in a phase 1 study, its experimental treatment for patients with spinal muscular atrophy was well tolerated. Spinal muscular atrophy is a neuromuscular disease that affects about 20000 people in Europe and the United
NEW YORK, April 3, 2012 /PRNewswire via COMTEX/ -- The Spinal Muscular Atrophy (SMA) Foundation announced today the launch of a biomarker assay panel for SMA using Myriad RBM's Multi-Analyte Profiling (MAP) technology platform.
TUCSON, Ariz., April 25, 2012 /PRNewswire-USNewswire/ -- Repligen Corp., in Waltham, Mass., announced today that its experimental drug RG3039, designed to treat spinal muscular atrophy (SMA), was safe and well-tolerated in a phase 1 clinical trial.
After Laura and Mike Canahuati of Houston, T.X. received the call from their neurologist which confirmed their worst fear: their little girl had been diagnosed with spinal muscular atrophy and had a mere 18 months to live. But Ryan also goes to
